NASDAQ:SGTX Sigilon Therapeutics (SGTX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$22.09▼$23.1050-Day Range$20.92▼$23.0652-Week Range$3.77▼$28.00Volume83,600 shsAverage Volume62,902 shsMarket Capitalization$56.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Sigilon Therapeutics alerts: Email Address Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Sigilon Therapeutics Stock (NASDAQ:SGTX)Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here SGTX Stock News HeadlinesMay 1, 2024 | benzinga.comLilly & Co Eli's Net WorthApril 14, 2024 | seekingalpha.comMCRB Seres Therapeutics, Inc.July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.October 22, 2023 | wsj.comBeam Therapeutics Inc.August 14, 2023 | markets.businessinsider.comEli Lilly Concludes Acquisition Of Sigilon TherapeuticsAugust 14, 2023 | finance.yahoo.comLilly Completes Acquisition of Sigilon TherapeuticsAugust 1, 2023 | finance.yahoo.comSGTX - Sigilon Therapeutics, Inc.July 31, 2023 | msn.comInside Eli Lilly's Strategic Investment In Sigilon: An Opportunity OverlookedJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 21, 2023 | businesswire.comSIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon ...July 18, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WMC, SGTX, AJX, IMNMJuly 6, 2023 | msn.comCanaccord Genuity Maintains Sigilon Therapeutics (SGTX) Buy RecommendationJuly 6, 2023 | msn.comSigilon Therapeutics (SGTX) Price Target Decreased by 6.27% to 48.28July 3, 2023 | msn.com5 big deal reports: Overstock snags Bed Bath & Beyond IP; Visa pays $1B for PismoJune 29, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Sigilon Therapeutics, Inc. BuyoutJune 29, 2023 | finance.yahoo.comModerna Billionaire Set to Score 3,000% Gain on Tiny BiotechJune 29, 2023 | finanznachrichten.deEli Lilly and Company: Lilly to Acquire Sigilon TherapeuticsJune 29, 2023 | msn.comHealth Care Company Eli Lilly Announces Acquisition of Sigilon TherapeuticsSee More Headlines Receive SGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sigilon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SGTX CUSIPN/A CIK1821323 Websigilon.com Phone617-336-7540FaxN/AEmployees62Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($12.2328) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,560,000.00 Net Margins-171.29% Pretax Margin-171.29% Return on Equity-83.07% Return on Assets-38.17% Debt Debt-to-Equity RatioN/A Current Ratio1.78 Quick Ratio1.78 Sales & Book Value Annual Sales$12.94 million Price / Sales4.36 Cash FlowN/A Price / Cash FlowN/A Book Value$15.68 per share Price / Book1.43Miscellaneous Outstanding Shares2,510,000Free Float2,351,000Market Cap$56.40 million OptionableNot Optionable Beta4.12 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Rogerio Vivaldi Coelho M.B.A. (Age 59)M.D., MBA, Pres, CEO & Director Comp: $924.67kMr. Philip Ashton-Rickardt Ph.D. (Age 59)Chief Scientific Officer Comp: $614.08kDr. Robert S. Langer Jr. (Age 74)Ph.D., Sc.D., SCD, Co-Founder & Member of Scientific Advisory Board Dr. Daniel G. Anderson Ph.D. (Age 53)Co-Founder & Member of Scientific Advisory Board Dr. Omid Veiseh Ph.D.Co-FounderDr. José Oberholzer M.D.Co-FounderDr. Arturo Vegas Ph.D.Co-FounderMr. Josias Fantato De Pontes M.B.A. (Age 56)CFO, Principal Accounting Officer & Treasurer Mr. Bernd Kullmann M.B.A.Sr. VP and Head of Operations & Project ManagementMr. Matthew P. Kowalsky J.D. (Age 50)Chief of Staff, Chief Legal and Admin. Officer & Sec. More ExecutivesKey CompetitorsShattuck LabsNASDAQ:STTKAbeona TherapeuticsNASDAQ:ABEOGeneration BioNASDAQ:GBIOTrevi TherapeuticsNASDAQ:TRVIGreenwich LifeSciencesNASDAQ:GLSIView All CompetitorsInsidersLilly & Co EliBought 1,718,493 shares on 8/11/2023Total: $25.64 M ($14.92/share) SGTX Stock Analysis - Frequently Asked Questions How were Sigilon Therapeutics' earnings last quarter? Sigilon Therapeutics, Inc. (NASDAQ:SGTX) issued its earnings results on Wednesday, November, 10th. The company reported ($8.19) earnings per share for the quarter, topping the consensus estimate of ($8.58) by $0.39. The business had revenue of $1.95 million for the quarter, compared to analyst estimates of $3.20 million. Sigilon Therapeutics had a negative trailing twelve-month return on equity of 83.07% and a negative net margin of 171.29%. When did Sigilon Therapeutics' stock split? Sigilon Therapeutics shares reverse split on Tuesday, May 23rd 2023. The 1-13 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Sigilon Therapeutics IPO? Sigilon Therapeutics (SGTX) raised $101 million in an initial public offering on Friday, December 4th 2020. The company issued 5,600,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity acted as the underwriters for the IPO. This page (NASDAQ:SGTX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sigilon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sigilon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
